Automated screening of sickle cells using a smartphone-based microscope and deep learning

TL;DR

This paper introduces a smartphone-based deep learning framework for automatic sickle cell detection in blood smears, achieving high accuracy and suitable for resource-limited settings.

Contribution

The study presents a novel deep learning approach combining image enhancement and segmentation for mobile sickle cell screening, improving diagnosis accessibility.

Findings

Achieved ~98% accuracy in sickle cell detection

Area-under-the-curve (AUC) of 0.998 demonstrates high reliability

Validated on blood smears from 96 patients, including 32 SCD cases

Abstract

Sickle cell disease (SCD) is a major public health priority throughout much of the world, affecting millions of people. In many regions, particularly those in resource-limited settings, SCD is not consistently diagnosed. In Africa, where the majority of SCD patients reside, more than 50% of the 0.2-0.3 million children born with SCD each year will die from it; many of these deaths are in fact preventable with correct diagnosis and treatment. Here we present a deep learning framework which can perform automatic screening of sickle cells in blood smears using a smartphone microscope. This framework uses two distinct, complementary deep neural networks. The first neural network enhances and standardizes the blood smear images captured by the smartphone microscope, spatially and spectrally matching the image quality of a laboratory-grade benchtop microscope. The second network acts on the output of the first image enhancement neural network and is used to perform the semantic segmentation between healthy and sickle cells within a blood smear. These segmented images are then used to rapidly determine the SCD diagnosis per patient. We blindly tested this mobile sickle cell detection method using blood smears from 96 unique patients (including 32 SCD patients) that were imaged by our smartphone microscope, and achieved ~98% accuracy, with an area-under-the-curve (AUC) of 0.998. With its high accuracy, this mobile and cost-effective method has the potential to be used as a screening tool for SCD and other blood cell disorders in resource-limited settings.